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Abstract Cystic Fibrosis (CF) is a monogenic disease caused by mutations in the cystic fibrosis
transmembrane conductance regulator (CFTR) gene, resulting in defective CFTR-mediated chloride
and bicarbonate transport, with dysregulation of epithelial sodium channels (ENaC). These changes
alter fluid and electrolyte homeostasis and result in an exaggerated proinflammatory response
driven, in part, by infection. We tested the hypothesis that NLRP3 inflammasome activation and
ENaC upregulation drives exaggerated innate-immune responses in this multisystem disease. We
identify an enhanced proinflammatory signature, as evidenced by increased levels of IL-18, IL-1b,
caspase-1 activity and ASC-speck release in monocytes, epithelia and serum with CF-associated
mutations; these differences were reversed by pretreatment with NLRP3 inflammasome inhibitors
and notably, inhibition of amiloride-sensitive sodium (Na+) channels. Overexpression of b-ENaC, in
the absence of CFTR dysfunction, increased NLRP3-mediated inflammation, indicating that
dysregulated, ENaC-dependent signalling may drive exaggerated inflammatory responses in CF.
These data support a role for sodium in modulating NLRP3 inflammasome activation.
DOI: https://doi.org/10.7554/eLife.49248.001
Introduction
Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease to affect Cauca-
sian populations. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) result
in reduced expression and function of the CFTR with the most common mutation (DF508/DF508)
resulting in inadequate processing of the protein and subsequent intracellular trapping in the endo-
plasmic reticulum (ER) (Elborn, 2016). Clinical manifestations of this debilitating condition include
repeated pulmonary infections, innate immune-driven episodes of inflammation and inflammatory
arthritis (Elborn, 2016; Whitsett and Alenghat, 2015; Bals et al., 1999; Montgomery et al., 2017).
The CFTR protein is widely expressed in a variety of cells and tissues where it functions as an anion
channel, conducting chloride (Cl-) and bicarbonate (HCO3-) ions, and as a regulator of a range of
epithelial transport proteins, including the epithelial sodium channel (ENaC) (Ko¨nig et al., 2002;
Konstas et al., 2003; Kunzelmann, 2003; Berdiev et al., 2009).
The NLRP3 inflammasome is an important inflammatory pathway in CF but there is little indication
as to whether this reflects underlying innate autoinflammation or activation in response to chronic
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bacterial, viral and fungal infections, including pathogens such as Pseudomonas aeruginosa, and
Burhkholderia cepacia complex (Iannitti et al., 2016; Rimessi et al., 2015; Montgomery et al.,
2017; Fritzsching et al., 2015; Kiedrowski and Bomberger, 2018). We propose that CF exhibits
many hallmarks of an autoinflammatory condition (Peckham et al., 2017; McGonagle and McDer-
mott, 2006; McDermott et al., 1999), with infiltration by innate immune cells (macrophages and
neutrophils) at target sites, and a lack of autoantibodies or autoreactive T cells (McDermott et al.,
1999). The NLRP3 intracellular protein complex is a sensor that detects changes in cellular homeo-
stasis rather than directly sensing common pathogenic or endogenous motifs. Multiple cellular
events have been observed to trigger NLRP3 activation, including K+ efflux, Na+ influx, Cl- efflux
and Ca2+ signalling (Schorn et al., 2011; Mun˜oz-Planillo et al., 2013; Katsnelson and George,
2013; Domingo-Ferna´ndez et al., 2017; Green et al., 2018; Hafner-Bratkovicˇ and Pelegrı´n,
2018). All known canonical inflammasomes, including the NLRP3 inflammasome, function as signal-
ling platforms for caspase-1-driven activation of IL-1-type cytokines (IL-1b and IL-18). One of IL-18’s
main functions is induction of cell-mediated immunity and IFN-g secretion by natural killer (NK) and
T-cells, whereas IL-1b has a central role in inducing fever with immune cell proliferation, differentia-
tion and apoptosis. Inflammasome activation induces a programmed cell death downstream of the
activation of caspases-1, 4, 5, and 11. Gasdermin D (GSDMD) is cleaved by said caspases, oligome-
rizing and forming pores (13 nm) in the plasma membrane, releasing mature IL-1b and IL-18 and trig-
gering cell lysis, or pyroptosis (Cookson and Brennan, 2001; Platnich and Muruve, 2019).
In healthy lungs, ENaC helps maintain normal volume and composition of airway surface liquid
(ASL). An absence or reduction in functional CFTR leads to defective CFTR-mediated anion transport
and upregulation of ENaC. These changes in normal homeostasis result in fluid hyperabsorption,
abnormally thick viscous mucus and defective mucociliary clearance (Althaus, 2013; Boucher, 2019).
While there is no literature to support a direct link between ENaC and inflammation in CF, there is
indirect evidence to suggest that aberrant sodium (Na+) transport influences the disease process.
Overexpression of b-ENaC in mice, results in CF-like lung disease, with ASL dehydration, inflamma-
tion and mucous obstruction of bronchial airways (Mall et al., 2004; Zhou et al., 2011; Zhou et al.,
2008). In humans, genetic variants in the b- and g- ENaC chains, leading to functional abnormalities
in ENaC, have been associated with bronchiectasis and CF-like symptoms (Fajac et al., 2008). By
contrast, rare mutations associated with hypomorphic ENaC activity, can slow disease progression in
patients homozygous for the CFTR DF508 mutation (Mall et al., 2004; Zhou et al., 2011;
Donaldson and Boucher, 2007). These studies highlight the essential role of ENaC in regulating
normal airway homeostasis and show that inhibition of ENaC may modify disease progression, either
by altering ASL composition or modifying other processes, such as inflammation. Several trials are
ongoing to assess the safety and effectiveness of new topical ENaC inhibitors to restoring airway
surface liquid and mucociliary clearance in CF (Cystic Fibrosis Foundation, 2017).
The aims of this study were to characterise NLRP3 inflammasome activation in CF and to investi-
gate the role of the epithelial Na+ channel, ENaC, in driving this inflammation through alterations in
ionic homeostasis, a known NLRP3 activating event.
In order to fulfil these aims, monocytes and epithelial cells with characterised CF-associated muta-
tions are directly compared to cohorts of NCFB and SAID.The NCFB cohort comprises of individuals
with primary ciliary dyskinesia (PCD), a rare, ciliopathic, autosomal recessive genetic disorder affects
the movement of cilia in the lining of the respiratory tract. Individuals with PCD suffer from reduced
mucus clearance from the lungs, and susceptibility to chronic recurrent respiratory infections, as is
the case with CF. By comparing monocytic- and epithelial-driven inflammation in CF and PCD, one is
able to distinguish between inflammation due to recurrent infection, as is the case with both CF and
NCFB, and inflammation that is downstream of CFTR/ENaC-mediated ionic disturbances, specific to
CF.
The SAID patient cohort is composed of an array of systemic autoinflammatory diseases that are
defined by an innate immune driven inflammation. The variety of autoinflammatory disorders
described in this manuscript demonstrates the broad range of pathophysiology within this rare
inflammatory disease spectrum. Here we demonstrate that the intrinsic ionic defect in cells and indi-
viduals with CF-associated mutations predisposes hyperactivation of the NLRP3 inflammasome, lead-
ing to inappropriate and destructive innate immune driven inflammation, as found in
autoinflammation.
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Results
Increased NLRP3-dependent IL-18 secretion in human bronchial
epithelial cells with CF-associated mutations
In CF, airway epithelial cells have been shown to produce exaggerated levels of proinflammatory
cytokines (IL-8 and TNF) characteristic of a hyper-inflammatory phenotype (Venkatakrishnan et al.,
2000). However, IL-1b secretion is barely detectable in bronchial/airway epithelial cells and does not
greatly increase following stimulus with NLRP3-inflammasome activators, despite being highly
responsive to the effects of the IL-1b cytokine itself (Tang et al., 2012; Peeters et al., 2013;
Gillette et al., 2013). We explored the effects of the constitutively expressed IL-18 cytokine in
HBECs (BEAS-2B (WT) control, IB3-1 (DF508/W1282X), CuFi-1 (DF508/DF508) and CuFi-4 (DF508/
G551D)) following treatment with activators for the four main caspase-1 driven inflammasomes,
NLRC4, pyrin, AIM2 and NLRP3 (Figure 1).
Under basal conditions, IL-18 levels in the HBECs were undetectable in the absence of a stimulus.
All inflammasomes were primed with lipopolysaccharide from Escherichia coli K12 (LPS), which spe-
cifically targets TLR4 and is used to promote pro-IL-18/IL-1b expression; this was followed by stimu-
lation with established activators of the inflammasomes, NLRC4 (flagellin), pyrin (TcdB) and AIM-2
(dsDNA). There were no differences between cells with or without CF-associated mutations for acti-
vation of these particular inflammasomes (Figure 1A). However, when HBECs were stimulated with
LPS, followed by ATP, a specific NLRP3 inflammasome activating signal that nucleates NLRP3 assem-
bly with ASC, pyrin and caspase-1, IL-18 secretion was upregulated in CF-associated mutant cell
lines, IB3-1 (p<0.0001) and CuFi-1 (p<0.0001) relative to the BEAS-2B control. When these cells
were pre-treated with small molecule inhibitors of the NLRP3 inflammasome signalling pathway
(MCC950; NLRP3, OxPAPC;TLR4, YVAD;caspases), IL-18 secretion was reduced (Figure 1B) in the
CF-associated mutant HBEC lines thereby confirming NLRP3 inflammasome as the source of the ele-
vated IL-18 inflammatory cytokine. Consistent with increased IL-18 cytokine levels, caspase-1 activa-
tion was also elevated in the CF-associated mutant HBEC lines relative to control post-LPS and ATP
stimulation in vitro, and was depleted by MCC950 pre-treatment (Figure 1C).
It is well established that NLRP3 inflammasome triggers sterile inflammatory responses and
pyroptosis, which is a proinflammatory form of programmed cell death initiated by the activation of
inflammatory caspases (Bergsbaken et al., 2009). To examine this, we monitored cell death
whereby pyroptosis was distinguished from necrosis by pretreating cells with a caspase inhibitor and
using lactose dehydrogenase (LDH) as a measure of necrosis. Elevated pyroptosis was present after
LPS and ATP stimulation in the HBEC line IB3-1 (Figure 1D), consistent with an NLRP3-mediated
hyper-inflammatory phenotype.
Increased NLRP3-dependent IL-1b/IL-18 secretion in human monocytes
with CF-associated mutations
We next explored NLRP3 inflammasome activation in primary monocytes (main producers of IL-18
and IL-1b, along with neutrophils) derived from HC, CF, SAID, and NCFB (Figure 2). Under basal
conditions primary monocytes, isolated from HC and CF, showed no significant difference in the
secretion of IL-18 and IL-1b cytokines (Figure 2A,B) or when monocytes were stimulated with LPS
alone across all patient groups (Figure 2—figure supplement 1A,B). As with the HBECs, there was
also no statistical difference between HC and CF in LPS mediated activation of inflammasomes,
NLRC4, pyrin and AIM-2.
In primary monocytes stimulated with LPS, followed by ATP to activate the
NLRP3 inflammasome, we observed hyper-responsiveness in IL-18 (p<0.0001) and IL-1b (p=0.0009)
secretion in CF monocytes relative to HC. When these cells were pretreated with
NLRP3 inflammasome pathway inhibitors (MCC950; NLRP3, OxPAPC;TLR4, YVAD;caspase-1), their
secretions were significantly abrogated across all patient groups (HC, CF, SAID and NCFB)
(Figure 2C,D). Downstream, IL-18 acts on NK and T-cells to express and secrete IFN-g (Kim et al.,
2015); we monitored IFN-g gene expression and secretion and found they were increased, post-
NLRP3-inflammasome activation, in PBMCs from patients with CF compared to HC (Figure 2—fig-
ure supplement 1C,D).
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We next examined cell death in HC, CF, SAID and NCFB monocytes (Figure 2G). Elevated pyrop-
tosis was present after LPS and ATP stimulation in monocytes from patients with CF, and also in
those diagnosed with SAID. Notably, caspase-1-independent necrosis was also elevated in CF and
SAID monocytes (Figure 2E). To understand the relationship between elevated pyroptosis and
downstream inflammation, the presence of ASC protein aggregates (specks), key inflammasome
components, were measured in the cell supernatants, post-NLRP3 inflammasome activation. ASC-
specks were elevated in stimulated monocytes from patients with CF-associated mutations, and also
in those diagnosed with SAID (Figure 2F), and were reduced with MCC950 treatment. Similar to
HBECs, caspase-1 activation was also elevated in CF and SAID monocytes, post-LPS and ATP stimu-
lation in vitro, and were depleted by MCC950 pretreatment in the monocytes (Figure 2E).
Figure 1. LPS-induced IL-18 secretion in human bronchial epithelial cells is higher in cells with CF-associated mutations and is NLRP3 inflammasome
dependent. Human bronchial epithelial cell (HBEC) lines (BEAS-2B (WT), IB3-1 (DF508/W1282X), CuFi1 (DF508/ DF508), CuFi4 (DF508/G551D) (n = 3
independent experiments) were unstimulated or stimulated with Lipopolysaccharide, from Escherichia coli K12 (LPS Ultrapure), which specifically targets
TLR4 (10 ng/mL) for 4 hr before being stimulated for 4 hr with Flagellin (10 ng/mL with Lipofectamine 2000) for NLRC4 inflammasome, TcdB (10 ng/mL)
for Pyrin inflammasome or poly(dA:dT) dsDNA (1 mg/mL with Lipofectamine 2000) for AIM2 inflammasome. ELISA assays were used to detect (A) IL-18.
To monitor NLRP3 inflammasome activation, HBEC (n = 3 independent experiments) were pre-incubated with MCC950 (15 mM), OxPAPC (30 mg/mL)
and YVAD (2 mg/mL) for 1 hr before a stimulation with LPS (10 ng/mL, 4 hr), and ATP (5 mM) for the final 30 min. ELISA assays were used to detect (B)
IL-18 and (D) colourimetric assay used to detect caspase-1 activity in protein lysates for LPS/ATP and LPS/ATP/MCC950). (D) Necrosis and pyroptosis
are represented as superimposed bar charts. Total necrosis was measured using LDH release assay. For pyroptotic cell death, each sample/condition
was repeated in parallel with a caspase-1 inhibitor (YVAD (2 mg/mL, 1 hr)) pre-treatment. The total necrosis level was then taken away from the
caspase-1 inhibited sample, or ‘caspase-1 independent’ necrosis, with the remaining LDH level termed ‘caspase-1 dependent necrosis’ or pyroptosis.
Cells were then stimulated with LPS (10 ng/mL, 4 hr), and ATP (5 mM) for final 30 min. The assay was performed with HBEC lines (n = 3 independent
experiments). () Significance for Total Necrosis (.) Significance for Pyroptosis. A 2-way ANOVA with Tukey’s multiple comparison test was performed (p
values * =< 0.05, ** =< 0.01, *** =< 0.001 and **** =< 0.0001).
DOI: https://doi.org/10.7554/eLife.49248.002
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Figure 2. LPS-induced IL-1b/IL-18 secretion in human monocytes is higher in CF and is NLRP3 inflammasome dependent. Primary monocytes from HC
and CF (HC, n = 10; CF, n = 10) were unstimulated or stimulated with LPS which specifically targets TLR4 (10 ng/mL) for 4 hr before being stimulated for
4 hr with Flagellin (10 ng/mL with Lipofectamine 2000) for NLRC4 inflammasome, or TcdB (10 ng/mL) for Pyrin inflammasome or poly(dA:dT) dsDNA (1
mg/mL with Lipofectamine 2000) for AIM2 inflammasome. ELISA assays were used to detect (A) IL-18 and (B) IL-1b cytokine secretion in supernatants. To
Figure 2 continued on next page
Scambler et al. eLife 2019;8:e49248. DOI: https://doi.org/10.7554/eLife.49248 5 of 24
Research article Human Biology and Medicine Immunology and Inflammation
Proinflammatory cytokines and ASC specks are elevated in CF Sera,
and are comparable to patients diagnosed with systemic
autoinflammatory disease (SAID)
To understand the extent of systemic inflammation in CF, serum cytokine levels were measured in
patients with CF, SAID, NCFB and HC. Serum IL-18 (p=0.0064), IL-1b (p<0.0001) and IL-1Ra
(p<0.0001) levels were all significantly elevated in CF samples, with levels comparable to SAIDs
(Figure 3A–C). However, in contrast to IL-1-type cytokines, the inflammasome-independent cyto-
kines, TNF and IL-6, were not significantly elevated in patients with CF whereas the levels of these
two cytokines were significantly elevated in samples from patients with SAID (Figure 3—figure sup-
plement 1). All SAID patients were on active recombinant IL-1Ra (anakinra) therapy, which will have
reduced serum cytokine levels. However, levels of IL-18 and endogenous IL-1Ra were raised in
patients with SAID, and are comparable to the proinflammatory IL-1 cytokines found in CF-serum.
We next sought to confirm that serum IL-1-type cytokines were associated with NLRP3 inflamma-
some activation by detecting the presence of ASC specks, in sera. ASC-specks were significantly ele-
vated in CF (p=0.0007) and SAID sera compared to HC (Figure 3D), reflecting inflammasome-
mediated inflammation and pyroptosis (Franklin et al., 2014). The activity of caspase-1, the rate-lim-
iting factor in the activation of all inflammasomes (Mariathasan et al., 2006), was significantly ele-
vated in CF and SAID serum samples compared to NCFB and HC (Figure 3E).
These data suggest that systemic serum cytokine levels from patients with CF are comparable to
patients diagnosed with SAID and can be characterised by release of proinflammatory IL-1-type
cytokine family members (IL-1b and IL-18), associated with NLRP3 inflammasome activation.
Dysregulated na+ and K+ in cells with CF-associated mutations can be
modulated with ENaC inhibitors
As K+ efflux and Na+ influx are thought to occur upstream of NLRP3 inflammasome activation and
ENaC overactivation is a recognised event in cells with CF-associated mutations, we monitored intra-
cellular concentrations of K+ and Na+ to determine if they were dysregulated in CF. The concentra-
tion gradient of Na+ and K+ is essential for cellular homeostasis, including resting potential, nutrient
transport, cell volume and signal transduction. Here we tested the hypothesis that dysregulated
ENaC-mediated Na+ transport alters the Na+/K+ gradient, enhancing K+ efflux and downstream
NLRP3 inflammasome activation. We found that intracellular Na+ levels were significantly higher in
CF cells [monocytes (p<0.0001), HBEC (p<0.0001)], at the peak of Na+ influx, which was recorded
immediately following stimulus with ATP. This corresponded with a superior reduction in intracellular
K+ [monocytes (p<0.0001), HBEC (p<0.0001)], suggestive of greater K+ efflux in these cells, upon
ATP stimulation (Figure 4A,B,E,F, Figure 4—figure supplement 1). The magnitude of the observed
Figure 2 continued
monitor NLRP3 inflammasome activation, primary monocytes from HC, CF, SAID and NCFB (HC, n = 10; CF, n = 10; SAID, n = 4; NCFB, n = 4) were
pre-incubated with MCC950 (15 mM), OxPAPC (30 mg/mL) and YVAD (2 mg/mL) for 1 hr before a stimulation with LPS (10 ng/mL, 4 hr), and ATP (5 mM)
for the final 30 min. ELISA assays were used to detect (C) IL-18 and (D) IL-1b cytokine secretion in supernatants and (E) a colourimetric assay was used
to detect caspase-1 activity in protein lysates (HC, n = 10; CF, n = 10; SAID, n = 4; NCFB, n = 4). (F) Flow cytometry was used to detect ASC specks in
supernatants of primary monocytes from HC, CF, SAID and NCFB (HC, n = 10; CF, n = 10; SAID, n = 6; NCFB, n = 4) for ±LPS/ATP and (HC, n = 5; CF,
n = 5) for MCC950 with LPS/ATP. (G) Necrosis and pyroptosis are represented as superimposed bar charts. Total necrosis was measured using LDH
release assay. For pyroptotic cell death, each sample/condition was repeated in parallel with a caspase-1 inhibitor (YVAD (2 mg/mL, 1 hr)) pre-
treatment. The total necrosis level was taken away from the caspase-1 inhibited sample, or ‘caspase-1 independent’ necrosis, with the remaining LDH
level termed ‘caspase-1 dependent necrosis’ or pyroptosis. Cells were then stimulated with LPS (10 ng/mL, 4 hr), and ATP (5 mM) for final 30 min. The
assay was performed with primary monocytes from HC, CF, SAID and NCFB (HC, n = 10; CF, n = 10; SAID, n = 4; NCFB, n = 4). () Significance for Total
Necrosis (.) Significance for pyroptosis. A 2-way ANOVA statistical test was performed, with Tukey post-hoc correction (p values * =< 0.05, ** =< 0.01,
*** =< 0.001 and **** =< 0.0001; error bars  SEM). Inhibitor treatments in panels a-c were found to significantly reduce cytokine secretion and
caspase-1 activity to **p =< 0.01 or less, for CF and SAID groups respectively. Significance values not displayed on the graph.
DOI: https://doi.org/10.7554/eLife.49248.003
The following figure supplement is available for figure 2:
Figure supplement 1. Primary monocytes from HC, CF, SAID and NCFB (HC n = 9, CF n = 9, SAID n = 4, NCFB n = 4) were unstimulated or stimulated
with LPS (10 ng/ml, 4 hr) or LPS (10 ng/ml, 4 hr) and ATP (5 mM) for the final 30 min.
DOI: https://doi.org/10.7554/eLife.49248.004
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Figure 3. Inflammatory serum cytokine signature in CF. (A) ELISA assays were used to detect IL-18 (HC, n = 10, CF, n = 30, SAID, n = 10, NCFB, n = 4),
(B) IL-1b (HC, n = 10, CF, n = 30, SAID, n = 10, NCFB, n = 4), (C) IL-1Ra (HC, n = 10, CF, n = 30, SAID, n = 7, NCFB, n = 4) in patient sera. Outliers in
SAID group for IL-1b and IL-1Ra correspond to HIDS one and A20 deficiency (D) Flow cytometry was used to detect ASC specks (HC, n = 10, CF,
n = 15, SAID, n = 10, NCFB, n = 4) in patient sera. (E) A colorimetric assay to detect caspase-1 activity in sera of patients with CF, SAID and NCFB as a
percentage of HC (HC, n = 10, CF, n = 15, SAID, n = 4, NCFB, n = 4). Of note, an undetermined amount of detected IL-1Ra is attributed to circulating
Anakinra (recombinant IL-1Ra) specifically in the SAID cohort. The Kruskal-Wallis non-parametric test, with Dunn’s multiple comparison test, was
performed (p values * =< 0.05, ** =< 0.01, *** =< 0.001 and **** =< 0.0001; error bars  S.E.M).
DOI: https://doi.org/10.7554/eLife.49248.005
The following source data and figure supplements are available for figure 3:
Source data 1. Serum cytokine levels for all patient groups.
DOI: https://doi.org/10.7554/eLife.49248.008
Figure supplement 1. Inflammatory serum cytokine signature in CF.
DOI: https://doi.org/10.7554/eLife.49248.006
Figure supplement 1—source data 1. Serum cytokine levels for all patient groups.
DOI: https://doi.org/10.7554/eLife.49248.007
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Figure 4. Dysregulated Na+ and K+ in cells with CF-associated mutations can be modulated with ENaC inhibitors. Intracellular Na+ was detected using
an AM ester of sodium indictor SBFI (S-1263) and (B, D) intracellular K+ was detected using an AM ester of potassium indictor PBFI (P-1266); changes in
fluorescence were measured by fluorimeter post-stimulation with 5 mM ATP in (A, B) monocytes (HC = 7, CF = 7) (E, F) HBECs (n = 3 independent
experiments). Cells were pre-treated with the following: amiloride (100 mM), S18 derived peptide (25 mM, 4 hr) with LPS (10 ng/mL, 4 hr) and ATP (5 mM)
Figure 4 continued on next page
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Na+ and K+ fluxes was significantly reduced by ENaC inhibition (using both amiloride and the
SPLUNC1-derived peptide, S18, a highly stable and specific small molecule inhibitor of ENaC chan-
nels). Pretreatment with 5-(N-ethyl-N-isopropyl)-amiloride, EIPA, a broad-spectrum Na+ channel
inhibitor with lower potency for ENaC, also reduced intracellular Na+ and increased intracellular K+
in CF monocytes and HBEC lines, but not to the same extent as amiloride or S18 (Figure 4A,B,E,F,
Figure 4—figure supplement 1). To corroborate our findings, we used ouabain, a Na+/K+-ATPase
inhibitor, which was associated with a higher intracellular Na+ in CF cells compared to HC. Collec-
tively, these data suggest that higher intracellular Na+ levels in CF, mainly driven by ENaC, predis-
pose cells to a greater K+ efflux upon stimulation with ATP. Na+ influx has been described as a
modulator of NLRP3 activation, dependent on K+ efflux (Schorn et al., 2011; Mun˜oz-Planillo et al.,
2013; Katsnelson and George, 2013).
As inhibition of ENaC activity (by amiloride and S18) modulated elevated intracellular Na+ levels
in cells with CF-associated mutations, we measured b-ENaC protein expression in HBEC lines and
found significantly increased expression, in CuFi-1 and CuFi-4 cells relative to BEAS-2B control
(p=<0.05) (Figure 4G,H). Furthermore, the b-ENaC gene was expressed in monocytes with a signifi-
cant increase in b-ENaC protein levels noted in CF monocytes compared to HC (p=<0.05) (Fig-
ure 4—figure supplement 1, Figure 4C,D).
Inhibition of amiloride-sensitive sodium channels modulates
inflammation in CF
We next sought to determine the extent to which dysregulated Na+ levels contribute to the
observed NLRP3 inflammasome activation in cells with CF-associated mutations. We utilised small
molecule inhibitors, for potent inhibition of ENaC, for in vitro NLRP3 inflammasome activation
assays. Notably, amiloride alleviated the augmented cytokine secretion, as well as caspase-1 activity
in both primary CF monocytes (IL-18 p=0.0001; IL-1b p=0.0272) and HBEC lines (Figure 5A,B,E)
(Montgomery et al., 2017; Fritzsching et al., 2015; Mall et al., 2004). S18 potently inhibited cyto-
kine secretion (IL-18 p=0.0052; IL-1b p=0.0100) and caspase-1 activity exclusively in cells with CF-
associated mutations (Figure 5C, Figure 5—figure supplement 1), whereas EIPA had no effect (Fig-
ure 5—figure supplement 1A,C,D,E). These data were replicated by nigericin activation of NLRP3,
used as a control for ATP, due to ATP’s ability to modulate other ionic channels (Figure 5—figure
supplement 2). To corroborate these findings, both amiloride (p<0.0001) and S18 (p=0003) inhib-
ited ASC-speck formation in CF monocytes (Figure 5D), and finally, inhibition of amiloride-sensitive
channels did not modulate TNF levels (Figure 5—figure supplement 1F), suggestive of a specific
ENaC-NLRP3 axis.
b-ENaC overexpression in BEAS-2B cells increases proinflammatory
cytokine secretion
In order to recapitulate the ENaC-NLRP3 axis, as revealed in this study, we overexpressed the b-
ENaC chain in the WT BEAS-2B line. This approach has been used previously in a b-ENaC Tg-mouse
model of CF, which recreated a CF-like lung disease state, with mucous plugging and excessive
inflammation (Mall et al., 2004; Zhou et al., 2011). Overexpression of b-ENaC induced elevated IL-
Figure 4 continued
for the final 30 min. A 2-way ANOVA with Tukey’s multiple comparison test was performed (p values * =< 0.05, ** =< 0.01, *** =< 0.001 and
**** =< 0.0001) (*) indicate significance when comparing HC with CF-associated mutants. (.) indicate significance between treatments within the same
cell line. (C) Endogenous b-ENaC protein expression was detected using western blot in BEAS-2B HBEC, HC and CF monocytes (C) and densitometry
analysis of total b-ENaC (bands A, B, C indicated on blot) was quantified in (D) for CF relative to HC (n = 3 independent experiments). (G) BEAS-2B,
IB3-1, CuFi-1 and CuFi-4 HBEC lines and densitometry analysis of total b ENaC (bands A, B, C indicated on blot) was quantified in (H) (n = 3
independent experiments). Band A represents complex N-Glycosylation, 110 kDa b-ENaC (found when associated as ENaC complex); Band B
represents Endo-H sensitive N-Glycosylation, 96 kDa b-ENaC; Band C represents immature non-glycosylated, 66 kDa b ENaC. The Mann-Whitney non-
parametric test was performed (p values * = 0.05).
DOI: https://doi.org/10.7554/eLife.49248.009
The following figure supplement is available for figure 4:
Figure supplement 1. Increased sodium influx in cells with CF-associated mutations.
DOI: https://doi.org/10.7554/eLife.49248.010
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Figure 5. Inhibition of amiloride-sensitive sodium channels modulates inflammation in cells with CF-associated mutations. ELISA assays were used to
detect IL-18 (A) and (B) IL-1b in monocytes from HC (n = 9 amiloride, n = 10 S18), patients with CF (n = 10), SAID (n = 4) and NCFB (n = 4) and IL-18 (E)
HBEC (n = 3, amiloride independent experiments) (F) HBEC (n = 3, S18 independent experiments). (C) Colourimetric assay was used to detect caspase-
1 activity in protein lysates (HC n = 11, CF n = 11) and (D) flow cytometry was used to detect ASC specks in supernatant of primary monocytes (HC
n = 5, CF n = 5). Cell stimulation was as follows: Amiloride (100 mM or 10 mM, 1 hr) or S18 derived peptide (25 mM, 4 hr) were used as a pre-treatment
before a stimulation with LPS (10 ng/mL, 4 hr) and ATP (5 mM) for the final 30 min. (E, F) SCNN1B over-expression in BEAS-2B cells increases pro-
inflammatory cytokine secretion. (E) BEAS-2B cells were transiently transfected with 10mg SCNN1B cDNA (+) or a pcDNA3.1 vector only control (-) for 48
hr then stimulated with LPS (10 ng/mL, 4 hr) and ATP (5 mM) for the final 30 min (n = 3 independent experiments). Cells were lysed and immunoblotted
for b-ENaC and b-actin. (F) ELISA assays were used to detect IL-18 in the supernatant fraction. A 2-way ANOVA with Tukey’s multiple comparison test
was performed (p values * = 0.05, ** = 0.01, *** = 0.001 and **** = 0.0001) (*) indicate significance, when comparing HC with CF. (.) indicate
significance between treatments within the same cell line.
DOI: https://doi.org/10.7554/eLife.49248.011
The following figure supplements are available for figure 5:
Figure supplement 1. Inhibition of amiloride-sensitive sodium channels modulates inflammation in cells with CF-associated mutations.
DOI: https://doi.org/10.7554/eLife.49248.012
Figure supplement 2. Inhibition of amiloride-sensitive sodium channels modulates inflammation in cells with CF-associated mutations.
DOI: https://doi.org/10.7554/eLife.49248.013
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18 secretion at baseline and after LPS and ATP stimulation (p=0.0003) (Figure 6B). These data sup-
port the hypothesis that excessive ENaC-mediated Na+ influx intrinsically drives NLRP3 inflamma-
some activation in CF.
Discussion
Here we have described our findings that IL-1-type cytokines were elevated in both monocytes and
serum of patients with CF, but two of the major inflammasome-independent cytokines, TNF and IL-
6, were not significantly elevated in these patients. In contrast to patients with SAID, these data sug-
gest that the proinflammatory cytokine response in CF has a predominant NLRP3 inflammasome
constitution. Furthermore, on NLRP3 inflammasome activation, IL-18 secretion was upregulated in
the CF-associated mutant cell lines, IB3-1 (p<0.0001) and CuFi-1 (p<0.0001) relative to the BEAS-2B
control, and these levels were reduced by treatment with small molecule inhibition of
NLRP3 inflammasome signalling, thereby confirming the NLRP3 inflammasome as a major source of
the elevated IL-18 inflammatory cytokine in these cells. Perhaps the most notable feature is the
uncovering of a molecular link between enhanced ENaC-dependent Na+ influx, observed in cells
with CF-associated mutations, and the exacerbated NLRP3 inflammasome activation. By pretreating
these cells with CF-associated mutations with small molecule inhibitors of ENaC, the exaggerated IL-
1-type cytokine response in vitro was diminished (Figure 7).
Bronchial epithelial cell (BEC) lines can produce significant quantities of IL-18 on stimulation but
secrete only negligible amounts of basal or stimulated IL-1b compared to hematopoietic cells
(Tang et al., 2012; Peeters et al., 2013; Gillette et al., 2013). In human BEC models, rhinovirus has
been associated with IL-1b release, a process accentuated by dual priming with both ATP and polyi-
nosine polycytidylic acid (Poly I:C, which interacts with TLR3) (Piper et al., 2013; Shi et al., 2012). In
general, IL-18 is the predominant cytokine secreted by non-myeloid cells, which are also capable of
having activated inflammasomes (Okazawa et al., 2004). This contrasts with PBMCs, which produce
large amounts of IL-1b, from both patients with CF and healthy controls (Tang et al., 2012). The dif-
ferential secretion of IL-18 and IL-1b, observed in this study is noteworthy, with IL-1b secretion being
undetectable in HBEC lines, under the conditions used. This disparity may reflect the function of
these two inflammasome-processed zymogens; IL-18 is a cytokine that induces recruitment of neu-
trophils and Th17 differentiation, as well as IFNg secretion, whereas IL-1b is an intrinsically more
destructive cytokine, acting systemically to induce fever, proliferation, differentiation, apoptosis and
sensitivity to pain. IL-1b secretion is tightly regulated by a highly controlled process, involving its
own gene expression as well as inflammasome priming and assembly, whereas IL-18 is constitutively
Figure 6. SCNN1B over-expression in BEAS-2B cells increases pro-inflammatory cytokine secretion. BEAS-2B cells were transiently transfected with
10mg SCNN1B cDNA (+) or a pcDNA3.1 vector only control (-) for 48 hr then stimulated with LPS (10 ng/mL, 4 hr) and ATP (5 mM) for the final 30 min
(n = 3 independent experiments). Cells were lysed and immunoblotted for b-ENaC and b-actin a). ELISA assays were used to detect IL-18 in the
supernatant b) fraction. A 2-way ANOVA with Tukey’s multiple comparison test was performed (p values * = 0.05, ** = 0.01, *** = 0.001 and
**** = 0.0001).
DOI: https://doi.org/10.7554/eLife.49248.014
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expressed and only depends on the two signals for inflammasome priming and assembly. In addi-
tion, IL-1b is rapidly sequestered, or secretion, by IL-1Ra and soluble IL-1RI and –RII, once secreted,
which makes IL-1b particularly difficult to assay and detect. The biological property of IL-1b underlies
the severe phenotype of the rare autoinflammatory disease, deficiency of the interleukin-1–receptor
antagonist (DIRA), caused by homozygous mutations in the IL1RN gene, which encoding the IL-1Ra
protein (Aksentijevich et al., 2009).
The primary consequence of mutations in the CFTR gene is defective CFTR anion transport and
upregulation of Na+ transport through dysregulation of ENaC (Muraglia et al., 2019;
Peckham et al., 1997). Under in vivo conditions, patients with CF have a more negative baseline air-
way and nasal potential difference compared to HC and shows an enhanced depolarising response
to amiloride, reflecting the inhibition of excessive ENaC mediated Na+ influx (Solomon et al., 2018).
In airway epithelial cells, increased basolateral Na/K-ATPase activity has also been reported
(Peckham et al., 1997). We hypothesised that dysregulation of Na+ transport might influence
NLRP3 inflammasome activation by increasing K+ efflux, a principal trigger for NLRP3 activation
(Schorn et al., 2011; Mun˜oz-Planillo et al., 2013; Katsnelson and George, 2013;
Katsnelson et al., 2015; Di et al., 2018; Qu et al., 2017; Zhu et al., 2017; Rivers-Auty and
Brough, 2015). We confirmed a dysregulation of Na+ and K+ transport by examining primary innate
Figure 7. A schematic diagram of the proposed excessive NLRP3 inflammasome activation observed in individuals and cells with CF-associated
mutations. Without functional CFTR, inhibition of ENaC currents is diminished leading to increased intracellular Na+ levels. Dysregulation of ENaC-
dependent Na2+ influx leads to increased K+ efflux (via unknown mechanism) and NLRP3 inflammasome activation, with subsequent release of IL-1b
and IL-18. In the CF airway, K+ efflux is exacerbated upon K+ channel stimulation by endotoxins, DAMPs or PAMPs, leading to aberrant NLRP3
inflammasome activation and excessive IL-1b and IL-18 secretion. Blocking ENaC currents with S18 peptide restores Na+ and K+ levels which reduces
NLRP3-mediated production of IL-1b and IL-18.
DOI: https://doi.org/10.7554/eLife.49248.015
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immune cells and HBEC lines with CF-associated mutations in vitro and discovered that excessive
ENaC-mediated Na+ flux, measured indirectly by dependent changes of fluorescence signal, corre-
late with an increased K+ efflux, an activating signal of the NLRP3 inflammasome and downstream
IL-18 and IL-1b secretion. We also show that the systemic serum cytokine signature from patients
with CF is comparable to patients diagnosed with SAID, characterised by release of proinflammatory
IL-1b and IL-18, which are associated with inflammasome activation. On exploration of the inflamma-
tion involved, we found a LPS-induced hyper-responsive NLRP3 inflammasome, exclusively in cells
with CF-associated mutations, comparable to monocytes from patients with SAID. It should be noted
that the SAID patient cohort is comprised of a variety of autoinflammatory diseases that have differ-
ing molecular pathophysiology and varying degrees of innate driven inflammation. This NLRP3
inflammasome activation extended beyond IL-18 and IL-1b secretion, with increased propensity for
pyroptotic cell death and associated release of NLRP3 inflammasome components, such as ASC,
and induction of IFN-g secretion in the PBMC population. This type of inflammation has similarities
to autoinflammation, particularly the IL-1/IL-18 inflammasome signature observed in serum and also
present in vitro. The significantly elevated levels of ASC specks in CF sera (Figure 3D), in addition to
the proinflammatory IL-1-type cytokine signature (Figure 3A–C), suggests the presence of a NLRP3
inflammasome agonist. A wide range of possible candidates for such an agonist(s) include infectious
pathogens (either CF or non-CF related), the patients’ metabolic milieu or, indeed, other unknown
agonists. Further work will be necessary to decipher the complex molecular mechanisms involved.
This study does not suggest that inflammation is independent of infections in individuals with CF but
that the response to said infections is intrinsically dysregulated and predisposed to excessive and
inappropriate degrees of inflammation.
Cystic fibrosis is a monogenic disease, yet consists of varying degrees of pathology depending
on the precise CFTR mutation and the extent to which the encoded CFTR protein is subsequently
transcribed, translated, folded within the ER, expressed on the plasma membrane, its stability on the
surface and its ability to conduct chloride and bicarbonate. There are well documented examples of
different classes of CFTR mutations that fail at each one of the above stages of CFTR expression and
function. The IB3-1 (DF508/W1282X) cell line is associated with the greatest amounts of inflamma-
tion. The W1282X mutation is associated with severe disease clinically, that can be attributed to little
to no protein expression. Inflammation in the IB3-1 cell line in vitro does not correlate with ENaC
protein expression. The underlying mechanism of an ENaC/NLRP3 axis driving inflammation in cells
with CF-associated mutations may not be common to all mutation classes. Notably, all of the cells
(monocytes and epithelia) had at least one DF508 allele. Whether the loss of control of ENaC expres-
sion and function observed in DF508 CFTR expressing cells is unique to this more common mutation
will require further study. It is important to note that inhibition of ENaC alleviated NLRP3 inflamma-
some-mediated inflammation in all cell lines (Figure 5E–F). While inflammation in CF is believed to
be driven predominantly by infection, many CFTR mutant animal models have shown that airway
inflammation and bronchiectasis can occur under sterile conditions (Montgomery et al., 2017;
Keiser et al., 2015; Rao and Grigg, 2006). For instance, in a CFTR knockout ferret model, inflam-
mation, bronchiectasis and mucus accumulation can develop in the absence of infection (Rose-
now, 2018). A recent study from the Australian Respiratory Early Surveillance Team for CF
highlights the association between pulmonary inflammation and structural lung disease in young chil-
dren with and without infection (Rosenow et al., 2019). IL-1b is detectable in bronchoalveolar
lavage (BAL) fluid from children with CF and is strongly correlated with neutrophil counts, indepen-
dent from detectable infection (Montgomery et al., 2018). The increased IL-1b neutrophil produc-
tion in BAL fluid from patients with CF appears to be driven via NLRP3 (McElvaney et al., 2018).
Autoinflammation is defined as an exaggerated inflammatory response, driven by dysregulated
innate immune cells, in the absene of antigen-driven T-cells, B-cells, or associated autoantibodies
(Peckham et al., 2017; McDermott et al., 1999; McDermott and Aksentijevich, 2002;
McGonagle and McDermott, 2006; Stoffels and Kastner, 2016). Adaptive immune cells may be
recruited in response to the downstream consequences of autoinflammation, with increased suscep-
tibility to infection, and progression to autoimmunity and hyperinflammation (Wekell et al., 2016).
In fact, we have shown that endoplasmic reticulum (ER) stress present in CF innate immune cells,
including neutrophils, monocytes and M1 macrophages, causes an exaggerated inflammatory
response (Lara-Reyna et al., 2019). Based on these data and cited literature, CF displays features of
autoinflammatory disease, in part driven by aberrant ionic fluxes and recurrent infections. The
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NLRP3 inflammasome can be primed by proinflammatory cytokines, such as TNF, although bacterial
components do provide a far more potent stimulus (Swanson et al., 2019; McElvaney et al., 2019).
Targeting the exaggerated inflammatory response without simultaneously predisposing individu-
als to infection remains an elusive goal which carries inherent (potential) risk. This was highlighted by
the termination of a study investigating a leukotriene B4- (LTB4) receptor antagonist for treatment of
lung disease in CF following a disproportionate incidence of respiratory serious adverse events
(Konstan et al., 2014). Treating inflammation remains a priority and multiple trials targeting various
anti-inflammatory pathways are ongoing (Cystic Fibrosis Foundation, 2017). There is evidence in
the literature of endotoxin tolerant monocytes from patients with CF, with reduced cytokine expres-
sion in response to repetitive endotoxin exposure (del Campo et al., 2011; del Fresno et al., 2009;
del Fresno et al., 2008). However, we propose that peripheral monocytes such as those used in this
study, are not constantly exposed to common pathogenic antigens that exist within the lung micro-
environment during infections. In fact, one may propose a scenario of trained immunity, where
innate immune cells hyper-respond to the recurrent infections with greater destructive consequen-
ces. Endotoxins are not the only inflammatory stimulus for NLRP3 inflammasome priming that exist
in the inflammatory milieu of the CF lung. Epithelial derived cytokines, neutrophilic extracellular
traps (NETs), necrotic cell death and subsequent damage associated molecular patterens (DAMPs)
may all induce transcription of IL-1b/IL-18 and other inflammasome components, independent of
endotoxins. A caveat of our study is that we have not tested the full array of DAMPs and pathogen
associated molecular patterns (PAMPs) that exist in the CF lung that may trigger the intrinsic predis-
position to NLRP3 inflammasome activation observed in this study.
The data here suggest that IL-18 may be a useful therapeutic target, by preventing adaptive cell
airway infiltration whilst maintaining a potent IL-1b response to infection (Gabay et al., 2018); how-
ever, NLRP3 activation exercises a protective role in animal models of induced colitis (Allen et al.,
2010), running contrary to the expectation that reduced NLRP3 expression might reduce inflamma-
tion in the bowel. Furthermore, IL-18 has an epithelial protective role in promoting repair of gut epi-
thelium (Zaki et al., 2010), and more ex vivo studies and CF disease models are required to
elucidate the benefits or hazards of IL-18 blockade. Anakinra is a viable therapeutic option for CF,
particularly with its short half-life and daily treatment regime allowing a more controlled dosage dur-
ing any inevitable infections. In fact a phase IIa clinical trial to evaluate safety and efficacy of subcuta-
nous administration of anakinra in patients with cystic fibrosis is in progress (EudraCT Number:
2016-004786-80). It is notable that inhibition of TLR4 signalling was the most effective means of
blocking NLRP3 activation in our study, which suggests that targeting this pathway may be a thera-
peutic option in CF (Keeler et al., 2019; Greene et al., 2008). These novel data, along with our
observation that decreased intracellular K+ levels upon stimulation with ATP in cells with CF-associ-
ated mutations, correlates with the characteristic and excessive ENaC-mediated Na+ transport, sug-
gest that CF-associated mutations lower the threshold for NLRP3 assembly, rather than priming this
key intracellular component of innate immune defenses.
Through inhibition of amiloride-sensitive Na+ channels, we were able to reduce NLRP3 inflamma-
some activation, and associated IL-18 and IL-1b secretion, in vitro. Notably, ENaC inhibition did not
modulate IL-18 and IL-1b secretion in monocytes from individuals with SAID, indicating the proposed
ENaC-NLRP3 axis is unique to CF-associated mutations. These findings highlight the importance of
excessive ENaC-mediated intracellular Na+ as a disease mechanism in CF, and also highlight its
potential as a therapeutic target. Targeting amiloride-sensitive Na+ channels such as ENaC to restor-
ing airway surface liquid and mucociliary clearance, has been previously attempted, using amiloride
in the 1990 s, with little efficacy, due to amiloride’s short half-life and limited effectiveness
(Graham et al., 1993).
In conclusion, we have shown that hypersensitive NLRP3 inflammasome activation in CF induces
proinflammatory serum and cellular profiles. Overexpression of b-ENaC, in the absence of CFTR dys-
function as well as dysregulation of amiloride-sensitive Na+ channel activity in CF, further potentiates
LPS-induced NLRP3 inflammasome activity. Both ENaC and NLRP3 are potential therapeutic targets
for reducing inflammation in patients with CF.
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Materials and methods
Key resources table
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Antibody Rabbit polyclonal
anti-SCNN1B
Avia Systems
Biology, San Diego
Cat# ARP72375_P050;
RRID: AB_2811256
WB
1:500
Antibody Goat polyclonal
anti-Rabbit IgG (H+L)
Poly-HRP Secondary
Antibody
ThermoFisher
Scientific
Cat# 32260;
RRID: AB_1965959
WB 1:4000
Antibody Rabbit polyclonal
anti-actin-b
GeneTex Cat# GTX109639,
RRID: AB_1949572
WB
1:20:000
Antibody Mouse monoclonal
Phycoerythrin
anti-ASC (TMS-1)
Biolegend Cat# 653903,
RRID: AB_2564507
5 mL/ ml
Cell line
(Homo-sapiens)
BEAS-2B cell line ATCC ATCC CRL-9609
Cell line
(Homo-sapiens)
IB3-1 ATCC ATCC CRL-2777
Cell line
(Homo-sapiens)
CuFi-1 cell line ATCC ATCC CRL-4013
Cell line
(Homo-sapiens)
CuFi-4 cell line ATCC ATCC CRL-4015
Commercial
assay or kit
MycoAlertTM Lonza Cat# LT07-118
Biological
samples
(Homo-sapiens)
Human
Blood Samples
St James’s
University Hospital
Health Research
Authority REC
reference 17/YH/0084
Chemical
compound, drug
Lymphoprep Axis Shield Cat# 1114544
Chemical
compound, drug
Pan Monocyte
Isolation Kit, human
Miltenyi Biotec Cat# 130-096-537
Chemical
compound, drug
Lipopolysacchride
Ultrapure EK
InvivoGen Cat# tlrl-eklps 10ng/ml
Chemical
compound, drug
MCC950 Cayman Chemical Cat# CAY17510-1 15 nM, 1 hr
Chemical
compound, drug
YVAD InvivoGen Cat# inh-yvad 2 mg/ mL,
1 hr
Chemical
compound, drug
OxPAPC InvivoGen Cat# tlrl-oxp1 30 mg/ mL, 1 hr
Chemical
compound, drug
Amiloride
(hydrochloride)
Cayman Chemical Cat# 26295 10 mM, 100 mM,
1 hr
Chemical
compound, drug
SPLUNC1-derived
peptide, S18
Gift from Spyryx
Biosciences, Inc
25 mM, 4 hr
Chemical
compound, drug
5-(N-ethyl-N-
isopropyl)-
Amiloride (EIPA)
Cayman Chemical Cat# 1154-25-2 10 mM, 1 hr
Chemical
compound, drug
Ouabain Torcis Bioscience Cat# 630-60-4 100 nM,
24 hr
Chemical
compound, drug
ATP InvivoGen Cat# tlrl-atpl 5 mM,
30 min
Chemical
compound, drug
poly(dA:dT) dsDNA InvivoGen Cat# tlrl-patn 1 mg/ mL,
1 hr
Chemical
compound, drug
TcdB Cayman Chemical Cat# CAY19665-50 10 ng/mL,
1 hr
Continued on next page
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Continued
Reagent type
(species) or
resource Designation
Source or
reference Identifiers
Additional
information
Chemical
compound, drug
Flagellin InvivoGen Cat# tlrl-pbsfla 10 ng/mL,
1 hr
Commercial
assay or kit
Pierce BCA
Protein Assay Kit
ThermoFisher
Scientific
Cat# 23225
Chemical
compound, drug
PhosSTOP Merck Cat# 4906845001
Chemical
compound, drug
Pierce Protease
Inhibitor Mini Tablets
ThermoFisher
Scientific
Cat# A32955
Chemical
compound, drug
Immobilon Western
Chemiluminescent
HRP Substrate
Merck Cat# WBKLS0500
Commercial
assay or kit
IL-1 beta Human
Matched Antibody Pair
ThermoFisher
Scientific
Cat# CHC1213 Assay sensitivity < 31.2 pg/mL
Commercial
assay or kit
IL-18 Human
Matched Antibody
Pair
ThermoFisher
Scientific
Cat# BMS267/2MST Assay sensitivity
78 pg/mL
Commercial
assay or kit
IL-6 Human Matched
Antibody Pair
ThermoFisher
Scientific
Cat# CHC1263 Assay sensitivity
15.6 pg/mL
Commercial
assay or kit
TNF alpha Human
Matched Antibody Pair
ThermoFisher
Scientific
Cat# CHC1753 Assay sensitivity < 15.6 pg/mL
Commercial
assay or kit
IL1RA Human Matched
Antibody Pair
ThermoFisher
Scientific
Cat# CHC1183 Assay sensitivity < 31.2 pg/mL
Chemical
compound, drug
(TMB) substrate
solution
Sigma Cat# T0440
Commercial
assay or kit
Caspase-1
Colorimetrix Assay
R and D Systems Cat# BF15100
Commercial
assay or kit
High-Capacity cDNA
Reverse Transcription
Kit
ThermoFisher
Scientific
Cat# 4368814
Recombinant
DNA reagent
SCNN1B
cDNA plasmid
Addgene Cat# 83429
Recombinant
DNA reagent
pcDNA3.1
cDNA plasmid
Gift from N.M Hooper,
Manchester
Chemical
compound, drug
sodium-sensitive
molecule SBFI
ThermoFisher
Scientific
Cat# S-1263 10 mM,
100 min
Chemical
compound, drug
potassium-sensitive
molecule PBFI
ThermoFisher
Scientific
Cat# P-1266 10 mM,
100 min
Chemical
compound, drug
Pluronic F-127 Sigma Cat# P2443
Software,
algorithm
GraphPad Prism7 Graphpad software
Clinical characteristics of patients
Patients with CF, systemic autoinflammatory diseases (SAID), non-CF bronchiectasis (NCFB) and
healthy controls (HC) were recruited from the Department of Respiratory Medicine and Research lab-
oratories at the Wellcome Trust Benner Building at St James’s Hospital. All SAID patients were on
Anakinra treatment, when blood samples were obtained. The study was approved by Yorkshire and
The Humber Research Ethics Committee (17/YH/0084). Informed written consent was obtained from
all participants at the time of the sample collection. Demographics are shown in Supplementary file
1. All CF donors were F508del/F508del homozygous (n = 30) with no sign of infection. Three of the
patients with NCFB had primary ciliary dyskinesia (PCD) and one patient with NCFB had an unknown
genotype. All patients with a SAID had characterised mutations in a known disease-causing gene
(Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) n = 2, Muckle-Wells n = 2,
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A20 haploinsufficiency n = 1, Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis
(PAAND) n = 1, Familial Mediterranean Fever (FMF) n = 2, Hyper IgD Syndrome (HIDS) n = 2 and
Schnitzler syndrome n = 1).
PBMC and monocyte isolation
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using the density gra-
dient centrifugation. Whole blood were mixed with equal volume of PBS, carefully layered onto of
Lymphoprep (Axis-Shield, Dundee, UK) and centrifuged at 1100xg for 20 min without brakes. The
white buffy layer was removed and washed twice in PBS by centrifuging at 1100xg for 10 min. PBMC
pellet was resuspended in complete RPMI medium (RPMI medium containing 10% heat inactivated
foetal bovine serum, 50 U/ml penicillin, 50 mg/ml streptomycin).
Monocytes were isolated by negative selection from PBMCs using the monocyte isolation kit II
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Pelleted PBMCs were resuspended in 30 ml
of buffer per 107 cells (autoMACS Rinsing Solution containing 0.5% BSA). This was mixed with 10 ml
FcR Blocking Reagent followed by 10 ml of biotin-conjugated antibodies and incubated at 4˚C for 10
min. Next 30 ml of buffer were added together with 20 ml of anti-biotin microbeads and incubated
for an additional 15 min at 4˚C. This whole mixture was washed with 2 ml of buffer and centrifuged
at 300 xg for 10 min. The cell pellet was resuspended in 500 ml of buffer and past down a MS column
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) on a magnetic stand. PBMCs (2  106/ ml)
and monocytes (1  106/ ml) were allowed to adhere overnight prior to experimentation.
Cell line culture
Human cell lines BEAS-2B (ATCC CRL-9609), CuFi-1 (ATCC CRL-4013), CuFi-4 (ATCC CRL-4015) and
IB3-1 (ATCC CRL-2777) were purchase from ATCC (UK) which ensures STR profiling of the cell lines
used. BEAS-2B and IB3-1 were cultured in LHC basal medium (Thermo Fisher Scientific, Loughbor-
ough, UK) supplemented with 10% FBS, 50 U/ml penicillin and 50 mg/ml streptomycin). CuFi-1 and
CuFi-4 were grown on Cell+ surface plates or flasks (Sarstedt, Leicester, UK) with LHC-9 medium
(Thermo Fisher Scientific, Loughborough, UK). All cells were cultured in a humidified incubator at 37˚
C, 5% CO2. Cells were used at 1  10
6/ ml. Cell lines were routinely tested for mycoplasma using
MycoAlertTM Mycoplasma Detection Kit Lonza catalog#: LT07-118, and were all negative.
Cell stimulations
Cells were pre-treated with the following compounds where indicated prior to NLRP3 stimulation;
MCC950 (15 nM, Cayman Chemical, Cambridge, UK) for 1 hr, YVAD (2 mg/ mL, Invivogen, San
Diego, California) for 1 hr, OxPAPC (30 mg/ mL, Invivogen) for 1 hr, Amiloride (10 mM, 100 mM, Cay-
man Chemical, Cambridge, UK) for 1 hr, EIPA (10 mM, Cayman Chemical) for 1 hr, SPLUNC1-derived
peptide, S18 (25 mM, gift from Spyryx Biosciences, Inc) for 4 hr or ouabain (100 nM, Cayman Chemi-
cal, Cambridge, UK) for 24 hr. Inflammasome stimulation was achieved using either LPS (10 ng/mL,
Ultrapure EK, Invivogen) for 4 hr with the addition of ATP (5 mM, Invivogen, San Diego, California)
for the final 30 min of stimulation, poly(dA:dT) dsDNA (1 mg/mL with Lipofectamine 2000, Invivogen,
San Diego, California) for 1 hr, TcdB (10 ng/mL, Cayman Chemical, Cambridge, UK) for 1 hr or flagel-
lin (10 ng/mL with Lipofectamine 2000, Invivogen, San Diego, California) for 1 hr for the final 1 hr of
the LPS stimulation. ATP was dissolved in pre-warmed at 37˚C medium (100 mM stock) and immedi-
ately (~2 min) added to the cells. All incubations were done in a humidified incubator at 37˚C, 5%
CO2. Supernatant, RNA and protein were collected and stored immediately following stimulation.
Cytokine quantification using ELISA
Cytokines from patient sera and cell cultured media were detected by ELISAs (IL-1 beta Human
Matched Antibody Pair, human IL-18 Matched Antibody Pair, IL1RA Human Matched Antibody Pair,
TNF alpha Human Matched Antibody Pair and IL-6 Human Matched Antibody Pair) (ThermoFisher
Scientific, Loughborough, UK), as per the manufactures recommendations. In general, ELISA plates
were coated with 100 ml cytokine capture antibody in PBS overnight at 4˚C. The plates were washed
three times with PBST (PBS containing 0.5% Tween 20) and the wells blocked in 300 ml assay buffer
(0.5% BSA, 0.1% Tween 20 in PBS) by incubating for 1 hr. The plates were washed twice with PBST
and 100 ml of sera/culture supernatants, together with appropriate standards, were added to wells
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in duplicates. Immediately 50 ml of detection antibody were added to all wells and incubated for 2
hr. After the incubation the plates were washed five times with PBST and 100 ml of tetramethybenzi-
dine (TMB) substrate solution (Sigma, Poole, UK) were added to all wells and incubated for 30 min.
Colour development was stopped by adding 100 ml of 1.8N H2SO4. And absorbance measured at
450 nm and reference at 620 nm. Note all incubation steps were done at room temperature with
continual shaking at 700 rpm. All data points are an average of duplicate technical replicates for
each independent experiment.
ASC protein aggregates (specks)
Methodology as previously published (Rowczenio et al., 2018). Briefly, patients’ sera or culture
media were incubated with 5 mL of phycoerythrin anti-ASC (TMS-1) antibody (Biolegend, London,
UK) for 1 hr, and analysed on the LSRII flow cytometer instrument (BD Biosciences, California).
Caspase-1 activity
A colorimetric assay (Caspase-1 Colorimetrix Assay, R and D Systems, Abingdon, UK) measured cas-
pase-1 activity, via cleavage of a caspase-specific peptide conjugated to a colour reporter molecule,
p-nitroalinine (pNA), performed on protein lysates and serum. All data points are an average of
duplicate technical replicates for each independent experiment. Protein concentrations in the lysate
were determined by BCA assay.
Detection of mRNA by RT-qPCR
Cells were washed in PBS, pelleted and immediately lysed in 1 ml TRIzol Reagent (Ambion Life tech-
nologies, Paisley, UK) and RNA extracted using the PureLink RNA mini kit (Ambion, Life technolo-
gies, Paisley, UK). Chloroform (200 ml) were added to each sample and mixed vigorously for 15 s and
left to stand for 2 min at room temperature. These were centrifuged at 12000 xg for 15 min at 4˚C.
The top clear phase was transferred to a fresh tube and mixed with equal volume of 70% ethanol.
This mixture was transferred to a spin cartridge, with a collection tube, and centrifuged at 12000 xg
for 15 s at room temperature. The waste was disposed of and the spin cartridge was centrifuged
one more time. The spin cartridge was washed 700 ml of wash buffer I and centrifuged at 12000 xg
for 15 s. A second wash with 500 ml wash buffer II (containing ethanol) were added to the spin car-
tridge and centrifuged at 12000 xg for 15 s followed by further spin for 1 min. RNA was recovered
by adding 30 ml of RNase free water to the spin cartridge, incubated for 1 min and centrifuged for 2
min.
The High Capacity cDNA Reverse Transcription kit (Applied Biosystems, California) was used to
convert the RNA to cDNA according to the manufacturer’s instructions. TaqMan assays were done
in the QuantStudio 5 Real-Time PCR instrument (Thermo Fisher Scientific, Loughborough, UK).
The Taqman primers used in this study are detailed below:
Gene Assay ID Dye
SCNN1B Hs01548617_m1 FAM
IFNG Hs00989291_m1 FAM
HPRT1 Hs02800695_m1 FAM
Transient transfection
BEAS-2B cells were transiently transfected with 10 mg of sodium channel epithelial one beta subunit
(SCNN1B) cDNA (Addgene, Teddington, UK) or pcDNA3.1 vector only control (gift from Professor
NM Hooper, Manchester University) using Lipofectamine 2000 (Thermo Fisher Scientific, Loughbor-
ough, UK) for 48 hr, as per manufacturers’ instructions. Cells were harvested, lysed in RIPA buffer
and protein concentrations were determined using the Pierce bicinchoninic acid (BCA) assay
(Thermo Fisher Scientific, Loughborough, UK).
Scambler et al. eLife 2019;8:e49248. DOI: https://doi.org/10.7554/eLife.49248 18 of 24
Research article Human Biology and Medicine Immunology and Inflammation
Western blotting
Samples were made up in dissociation buffer [1x dissociation buffer (100 mM Tris-HCl, 2% (w/v)
sodium dodecyl sulfate, 10% (v/v) glycerol, 100 mM dithiothreitol, 0.02% (w/v) bromophenol blue,
pH 6.8] and heated at 95˚C for 5 min, and equal protein concentration was loaded and resolved by
10% SDS-PAGE on Tris-glycine gels and then transferred to Hybond PVDF membranes (GE Health-
care, Buckinghamshire, UK). Following electrotransfer in Towbin buffer (25 mM Tris, 192 mM glycine,
and pH 8.3, 20% methanol) at 100 V for 1 hr, the membranes were blocked for 1 hr in blocking solu-
tion (PBS containing 0.1% Tween 20% and 5% (w/v) non-fat milk). After three washes in PBST (PBS
with 0.5% Tween 20), primary antibodies were incubated with PVDF membrane overnight at 4˚C.
The membrane was washed three times with PBST and secondary antibody-HRP conjugate were
added and incubated for 2 hr with constant rocking at room temperature. The membrane was
washed five times with PBST and 3 ml of ECL detection system (Immobilon chemiluminescent HRP
substrate, Millipore, UK) was added onto the membrane for 5 min, before being imaged with the
ChemiDoc Imaging system (Bio-Rad, Hertfordshire, UK). Primary antibodies used: rabbit anti-
SCNN1B (Avia Systems Biology, San Diego; 1/500 dilution), rabbit anti-actin-b (GeneTex, Notting-
ham, UK) at 1/20000 dilution. Secondary antibodies used: anti-rabbit IgG horseradish peroxidase-
conjugated (Cell Signalling Technology, Hertfordshire, UK) were diluted at 1/4000. All antibodies
were diluted in PBS containing 0.1% Tween 20% and 2% BSA.
Fluorometric determination of na+ and K+ concentration
Na+ and K+ sensitive dyes, SBFI (S-1263) and PBFI (P-1266) (Molecular Probes, Paisley, UK), respec-
tively, were used as cell permeant selective ion indicators for the fluorometric determination of Na+
and K+ concentrations. Monocytes and HBECs were allowed to adhere in black 96-well cell culture
plates overnight. Cells were then incubated with various stimulants, as indicated in figure legends,
before being washed and incubated in the appropriate low serum media (see above) (1%) for 1 hr.
The dyes (10 mM final concentration) were loaded with Pluronic F-127 (Sigma) and incubated for
100 min. All wells were washed with NaCl solution. ATP (5 mM) was then added to the wells prior to
measuring fluorescence. Excitation at 344 nm and 400 nm with emission at 500 nm was measured
immediately to calculate the percentage change in fluorescence compared to an untreated control.
All data points are an average of duplicate technical replicates for each independent experiment.
Statistics
All analyses were performed using GraphPad Prism v 7. Bar graphs were expressed as mean stan-
dard error of the mean (S.E.M). The Kruskal-Wallis test with Dunn’s multiple comparison or the Mann
Whitney test was performed when comparing non-parametric populations. A two-way ANOVA sta-
tistical test with Tukey’s multiple comparison post-hoc analysis was performed when calculating vari-
ance between samples (p values * = 0.05, ** = 0.01, *** = 0.001 and ****=0.0001). A p<0.05
was considered significant. Statistical tests used are indicated in the figure legends. p-values are
measured using a 2-sided hypothesis.
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